Skip to main content
. 2018 May 24;13(5):e0197583. doi: 10.1371/journal.pone.0197583

Fig 3. Forest plot of pooled odds ratios (with 95% CI) of various adverse drug events for FDA-approved direct oral anticoagulants versus warfarin for thromboembolic stroke prophylaxis in non-valvular atrial fibrillation.

Fig 3